Nevertheless, as compared with controls, the risk increased 5.16, 8.28 and 4.10-fold, respectively, for NSCLC with promoter hypermethylation of the p16, DAPK or RARβ gene in smokers with CYP1A1 variants (Aa+aa). Here, CYP1A1 is linked to non-small cell lung carcinoma.